NeuroPharmac 2019 – NeuroPharmac Journal

Autism Spectrum Disorder: Medications overview https://doi.org/10.37881/1.411

2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome https://doi.org/10.37881/1.412

2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review https://doi.org/10.37881/1.413

2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura https://doi.org/10.37881/1.414

2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review https://doi.org/10.37881/1.415

2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
Siponimod: A new approved oral drug to treat multiple sclerosis https://doi.org/10.37881/1.421

2019, Volume 4, Issue 2 (May-August) [Download Full PDF]
Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease https://doi.org/10.37881/1.422

2019, Volume 4, Issue 2 (May-August) [Download Full PDF]
FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies? https://doi.org/10.37881/1.431

2019, Volume 4, Issue 3 (September-December) [Download Full PDF]
Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health https://doi.org/10.37881/1.432

2019, Volume 4, Issue 3 (September-December) [Download Full PDF]

Tweets by NeuroPharmac_J


                                                            
                                    Indexing


                
                    
                                                    © 2016 All rights reserved | NeuroPharmac Journal                                            
                    
                    Proudly powered by WordPress
                     | 
                    Theme: SuperMag by Acme Themes